| Interpretive Data: |
Background Information for Alport Syndrome, X-linked (COL4A5) Sequencing:
Characteristics: Progressive renal and cochlear disease with 30-40 percent incidence of ocular involvement; 60 percent of males reach end stage renal disease by age 30 and 85 percent have sensorineural deafness by age 40.
Incidence: Estimated to be between 1 in 5,000 to 1 in 50,000 live births.
Inheritance: X-linked recessive; de novo mutations in 10-15 percent of affected males.
Penetrance: Variable depending on mutation and sex..
Cause: Type 4 collagen (COL4A5) alpha chain mutations.
Clinical Sensitivity: Greater than 80 percent for X-linked Alport syndrome.
Methodology: Bidirectional sequencing of the entire COL4A5 coding region and intron-exon boundaries.
Analytical Sensitivity & Specificity: 99 percent.
Limitations: Rare diagnostic errors can occur due to primer site mutations. Regulatory region and deep intronic mutations will not be detected. Large deletions/duplications will not be detected in females. Mutations in genes other than COL4A5 are not evaluated.
Counseling and informed consent are recommended for genetic testing. Consent forms are available online at www.aruplab.com.
Refer to Statement C under Testing Information at http://www.aruplab.com.
|
| CPT Code(s): |
83891 Isolation; 83898 x46 Amplification; 83904 x46 Sequencing; 83909 x2 capillary electrophoresis; 83912 Interpretation and report. - Additional CPT code modifiers may be required for procedures performed to test for oncologic or inherited disorders.
|
|
![[ image for: Patient History for Alport Syndrome Testing]](icon_41.jpg){kind=icon}